Pieris Pharmaceuticals, Inc. (PIRS)
| Market Cap | 21.20M |
| Revenue (ttm) | 1.35M |
| Net Income (ttm) | -15.95M |
| Shares Out | 1.32M |
| EPS (ttm) | -12.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,008 |
| Open | 15.59 |
| Previous Close | 15.47 |
| Day's Range | 15.59 - 16.25 |
| 52-Week Range | 6.20 - 22.32 |
| Beta | 0.66 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2024 |
About PIRS
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partners... [Read more]
Financial Performance
In 2023, Pieris Pharmaceuticals's revenue was $42.81 million, an increase of 65.28% compared to the previous year's $25.90 million. Losses were -$24.54 million, -26.25% less than in 2022.
Financial StatementsNews
Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference
Poster presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of the Phase 3 S...
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders
NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc. - PIRS
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pieris Pharmac...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Pieris Pharmaceuticals, Inc.
NEW YORK , July 24, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and its board of directors concerning the p...
Dr. Vince Clinical Research Presents Groundbreaking Webinar on Accelerating Clinical & Drug Development Timelines with AI
OVERLAND PARK, Kan.--(BUSINESS WIRE)-- #AI--Dr. Vince Clinical Research presents a webinar on accelerating clinical and drug development timelines with AI on Sept. 11, 2024, at 2:00 p.m. ET.
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there a...
Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split
BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's common st...
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
BOSTON, MA / ACCESSWIRE / March 27, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) provided a corporate update today announcing a strategy to maximize its ability to capture the potential milestone...
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® techn...
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
BOSTON, MA / ACCESSWIRE / July 18, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolo...
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
BOSTON, MA / ACCESSWIRE / June 21, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolo...
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolo...
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog...
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog...
Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites
Expanding Elarekibep (AZD1402) trial finally has active/completed sites. Major investment risk exists because of the Company's cash burn rate.
Pieris Pharmaceuticals, Inc. (PIRS) Q1 2023 Earnings Call Transcript
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ET Company Participants Thomas Bures - CFO Stephen Yoder - President and CEO Shane Olwill - Chief Deve...
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MAY 10, 2023, AT 8:00 AM EDT Enrollment for elarekibep (PRS-060/AZD1402) Phase 2a study for asthma continues to progress with topline clin...
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
BOSTON, MA / ACCESSWIRE / May 4, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
BOSTON, MA / ACCESSWIRE / May 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technolog...
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
BOSTON, MA / ACCESSWIRE / April 17, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technol...
Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call Transcript
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Results Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Thomas Bures - Senior Vice President and Chief Financial Officer Ste...
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MARCH 29, 2023, AT 8:00 AM EDT Continued advancement of pipeline, including two clinical-stage inhaled respiratory programs and additional...
Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
BOSTON, MA / ACCESSWIRE / March 24, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) ,a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technol...
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tech...